Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Bought by Quarry LP

Quarry LP grew its position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 54.5% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 8,500 shares of the biotechnology company’s stock after purchasing an additional 3,000 shares during the quarter. Quarry LP’s holdings in Arrowhead Pharmaceuticals were worth $221,000 at the end of the most recent reporting period.

Other large investors have also made changes to their positions in the company. Creative Planning boosted its holdings in Arrowhead Pharmaceuticals by 9.4% in the second quarter. Creative Planning now owns 28,276 shares of the biotechnology company’s stock worth $735,000 after acquiring an additional 2,420 shares in the last quarter. Algert Global LLC boosted its holdings in Arrowhead Pharmaceuticals by 104.3% in the second quarter. Algert Global LLC now owns 40,466 shares of the biotechnology company’s stock worth $1,052,000 after acquiring an additional 20,656 shares in the last quarter. The Manufacturers Life Insurance Company boosted its holdings in Arrowhead Pharmaceuticals by 1.1% in the second quarter. The Manufacturers Life Insurance Company now owns 149,156 shares of the biotechnology company’s stock worth $3,877,000 after acquiring an additional 1,677 shares in the last quarter. Millennium Management LLC boosted its holdings in Arrowhead Pharmaceuticals by 61.9% in the second quarter. Millennium Management LLC now owns 529,251 shares of the biotechnology company’s stock worth $13,755,000 after acquiring an additional 202,280 shares in the last quarter. Finally, Deerfield Management Company L.P. Series C acquired a new stake in Arrowhead Pharmaceuticals in the second quarter worth about $506,000. 62.61% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Stock Performance

NASDAQ ARWR opened at $19.37 on Tuesday. The business has a fifty day moving average price of $23.57 and a 200 day moving average price of $24.77. Arrowhead Pharmaceuticals, Inc. has a one year low of $19.07 and a one year high of $39.83. The company has a market cap of $2.41 billion, a P/E ratio of -4.56 and a beta of 0.96.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) last posted its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($1.38) EPS for the quarter, missing the consensus estimate of ($0.58) by ($0.80). Arrowhead Pharmaceuticals had a negative net margin of 163.32% and a negative return on equity of 152.95%. During the same period last year, the company earned ($0.96) earnings per share. The business’s quarterly revenue was down 100.0% on a year-over-year basis. As a group, sell-side analysts predict that Arrowhead Pharmaceuticals, Inc. will post -4.31 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently commented on ARWR shares. The Goldman Sachs Group started coverage on Arrowhead Pharmaceuticals in a research report on Wednesday, June 5th. They issued a “neutral” rating and a $31.00 target price on the stock. StockNews.com upgraded Arrowhead Pharmaceuticals to a “sell” rating in a research report on Thursday, August 1st. Royal Bank of Canada reiterated an “outperform” rating and issued a $42.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Thursday, September 26th. B. Riley reiterated a “buy” rating and issued a $55.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Monday, August 12th. Finally, Cantor Fitzgerald reiterated an “overweight” rating on shares of Arrowhead Pharmaceuticals in a research report on Monday, September 9th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat, Arrowhead Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $43.25.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.